###### Strengths and limitations of this study

-   This study innovatively explores the relationship between end-of-life indicators used to identify patients with advanced chronic conditions (PACC) and the three archetypal end-of-life trajectories: acute (typically cancer), intermittent (typically organ failure) and gradual dwindling (typically dementia or frailty).

-   Analysing the characteristics of end-of-life indicators allows us to know which indicators most consistently identify patients for palliative care (PC). It also provides data on the characteristics that most commonly occur in each end-of-life trajectory.

-   The large number of identified PACC but with no advanced disease criteria reveals that there is a real and not previously well-described cohort of people with advanced frailty and PC needs.

-   These concepts are useful for clinical decision-making, for policymakers in designing appropriate health services, as well as giving researchers a theoretical framework for future research.

-   Study limitations include the heterogeneity in the collection of variables due to the multiple assessments from all healthcare system resources and the number of missing data in some variables.

Introduction {#s1}
============

Two concepts can be combined to illuminate care provision for patients with advanced chronic conditions (PACC): early identification of patients with palliative care (PC) needs and, second, end-of-life trajectories associated with advanced chronic illnesses. This gives a conceptual framework to understand the different characteristics of patients from their early identification for PC onwards.

Early identification of patients with PC needs {#s1a}
----------------------------------------------

The modern approach to the end-of-life divides this into two transitions[@R1] ([figure 1](#BMJOPEN2016012340F1){ref-type="fig"}). The first one, frequently some months or years before death, may constitute the starting of the process of identification of patients with PC needs, due to the appearance and recognition of some indicators or variables which make early identification easier. Throughout the article, we will refer to these patients with advanced chronic diseases and conditions, PC needs and limited life prognosis as 'patients with advanced chronic conditions' (PACC). The second transition---or 'the last days or weeks of patient\'s life'---starts when the terminal decline begins and corresponds to the out-moded paradigm of very late PC provision.

![Key transitions and the three end-of-life trajectories. Early identification of palliative care needs becomes the starting point for transition 1. Situational diagnosis refers to the evaluation and assessment of patients that allows healthcare professionals determine patients' health degree (A, B, C, D or E) and identify entrance to transition 2 (D) or last days--hours situation, instead (E); this situational diagnosis is indispensable to establish the objectives of care in this progressive care model in a decision-making process shared by professionals, patients and their families.](bmjopen2016012340f01){#BMJOPEN2016012340F1}

Early identification for PC has shown many benefits: it helps to clarify treatment preferences and goals of care, improves quality of life and symptom control, reduces distress, allows less aggressive care, lower spending, and may even lengthen survival.[@R2] Thus, to develop anticipatory PC[@R5] becomes crucial during this first transition.

A certain degree of prognostic approach may be used with caution in the care of individual patients, and professionals still have difficulties finding unequivocal prognostic variables.[@R6] Prognosis will always imply a degree of uncertainty,[@R7] since end-of-life processes are multifactorial and strictly individual at the same time. Besides, the earlier we want to identify these patients, the more difficult it becomes to obtain certain prognostic variables.[@R8]

Thus, although certain variables are broadly linked with mortality risks, there is no single prognostic indicator that identifies all patients who will die soon.[@R6] The classic prognosis approach focused on advanced chronic disease severity criteria has limitations: prognostic disease-centred variables, when used in isolation, have shown low prognostic capacity,[@R9] particularly for geriatric patients with multiple chronic conditions.[@R6] Other general factors have proved to be more reliable end-of-life prognostic indicators than disease-centred variables:[@R15] functional,[@R16] nutritional[@R20] and cognitive status;[@R25] [@R26] emotional problems;[@R27] [@R28] geriatric syndromes such as delirium,[@R29] [@R30] dysphagia,[@R31] pressure ulcers[@R32] and repetitive falls;[@R33] symptoms such as dyspnoea[@R34] and anxiety;[@R37] social vulnerability[@R38] or use of resources.[@R42]

Thus, most screening tools for identification of patients with PC needs[@R45]---for example, the Prognostic Indicator Guidance of the Gold Standards Framework (PIG-GSF),[@R46] the Supportive and Palliative Care Indicators Tool (SPICT),[@R47] the RADboud indicators for PAlliative Care needs (RADPAC)[@R48] and the NECesidades PALiativas CCOMS-ICO tool (NECPAL CCOMS-ICO tool)[@R49]---have incorporated these general conditions from different domains in different degrees.

The evaluation of these variables---disease specific and these other general factors---has also shown the need for complementing the static status (severity) with an assessment of dynamic progression of decline.[@R8]

End-of-life trajectories {#s1b}
------------------------

In 2003, Lunney *et al*[@R52] described three distinct illness trajectories of functional decline at the end of life ([figure 1](#BMJOPEN2016012340F1){ref-type="fig"}), illustrating the typical dynamic patterns of a group of patients classified according to their main chronic disease. The first clinical trajectory, typically associated to cancer, features a stable and/or low decline phase broken up by a severe decline in the last few weeks. The second features a gradual decline, with acute episodes usually related to concomitant processes and disease evolution and partial recovery; this trajectory corresponds to patients with advanced organ diseases such as heart, lung, renal and liver failure. Finally, the third trajectory shows a progressive slow-pace decline, typically related to dementia or frail patients.

Later, Murray *et al*[@R53] highlighted the clinical implications of end-of-life trajectories by presenting trajectories as a framework to help professionals and patients facing the uncertainty of having an advanced chronic condition avoid a prognostic paralysis. First, these trajectories may help clinicians to better plan care to meet their patients\' changing needs and help patients and caregivers to cope with their situation. Second, by pointing out that different models of care may be necessary to reflect and tackle patients\' different experiences and needs. Third, by graphing dimensional end-of-life trajectories, the different dimensions of need---physical, social, psychological and spiritual---may be identified and addressed.

Hypothesis and objectives {#s1c}
-------------------------

We hypothesise that there might be a common denominator in the characteristics of some indicators that would allow us to identify PACC at specific time points. On the other hand, distinguishing features may also exist in other indicators that support and develop the conceptual model of end-of-life trajectories.

Learning from the characteristics and evolution of these end-of-life indicators as the basis of the individual situational diagnosis[@R8]----understood as the assessment to determine patients\' health degree and (or possible) closeness to end-of-life situation ([figure 1](#BMJOPEN2016012340F1){ref-type="fig"})---can help clinicians to manage uncertainty and make better clinical decisions, according to patients\' values and preferences.[@R54] In order to develop further knowledge on these indicators, we analysed the characteristics and distribution of the indicators related to end of life in a cohort of patients identified with the NECPAL CCOMS-ICO tool.

Methods {#s2}
=======

Our methods, as extensively described elsewhere,[@R51] are reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations.[@R55] This study was formally approved by the ethical research committees of institutions involved in its execution (2010/PREVOsona: P10/65 and EO65).

Study design and setting {#s2a}
------------------------

A cross-sectional study of patients identified in a previous population-based study was conducted.[@R51] The study was conducted in the Spanish district of Osona, Barcelona, a mixed urban--rural district with a population of 156 087 residents, 21.4% of whom are aged \>65 years, with an annual mortality rate of 8.81 per 1000 inhabitants. Three selected primary care services and an acute care hospital, an intermediate care centre and four nursing homes serving these primary care services agreed to participate.

Eligibility criteria and participant selection {#s2b}
----------------------------------------------

Case selection was undertaken from November 2010 to October 2011. There were no exclusion criteria. Patient recruitment was made using the NECPAL CCOMS-ICO tool through the healthcare records and by interviews with healthcare professionals (doctors and nurses). 'NECPAL positive (+)' patients were defined as being surprise-question[@R56] answer 'no' ("I would not be surprised if this patient were to die in the next 12 months") and having at least one subsequent positive category: (1) category 1: choice, request or need of PC approach (has the patient or the main caregiver requested palliative/comfort treatments exclusively or suggests limitation of therapeutic effort? Healthcare professionals consider that the patient requires palliative care or palliative treatment at this moment?); (2) category 2: general clinical prognostic indicators of severity and progression, including comorbidity and resource use ([table 1](#BMJOPEN2016012340TB1){ref-type="table"}) or (3) category 3: disease-specific prognostic indicators ([table 2](#BMJOPEN2016012340TB2){ref-type="table"}).

###### 

Category 2 of the NECPAL CCOMS-ICO tool: general indicators of severity and progression

  Domain                                       Severity                                                                                                                                                                                                 Progression (in the last 6 months)
  -------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Functional markers                           Serious established functional dependence (Barthel Score \<25, ECOG \>2 or Karnofsky Score \<50%)                                                                                                        Loss of two or more ADLs even though there is adequate therapeutic intervention or clinical perception of functional decline (sustained, intense/severe, progressive, irreversible) not related to concurrent conditions
  Nutritional markers                          Serum albumin \<2.5 g/dL, not related to acute episodes of unbalance                                                                                                                                     Weight loss \>10% or clinical perception of nutritional decline (sustained, intense/severe, progressive, irreversible) not related to concurrent conditions
  Cognitive                                    Unable to dress, wash or eat without assistance (GDS/FAST 6c), urinary and faecal incontinence (GDS/FAST 6d--e) or unable to communicate meaningfully---six or less intelligible words (GDS/FAST 7)      Loss of two or more ADLs in the last 6 months, despite adequate therapeutic intervention (invaluable in hyperacute situation due to concurrent processes) or difficulty swallowing, or denial to eat, in patients who will not receive enteral or parenteral nutrition
  Emotional                                    Presence of emotional distress with psychological symptoms (sustained, intense/severe, progressive) not related to acute concurrent conditions                                                           
  Geriatric syndromes (in the last 6 months)   Persistent pressure ulcers (stages III--IV), recurrent infections (\>1), delirium, persistent dysphagia, falls (\>2)                                                                                     
  Comorbidity                                  Charlson Index                                                                                                                                                                                           
  Additional factors on use of resources       Two or more urgent (unplanned) hospital (or skilled nursing facilities) admissions due to chronic disease in the last yearNeed of complex/intense continuing care, either at an institution or at home   

ADL, activities of daily living; ECOG, Eastern Cooperative Oncology Group; GDS/FAST, Global Deterioration Scale/Functional Assessment Staging.

###### 

Category 3 of the NECPAL CCOMS-ICO tool: disease-specific indicators

  ------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancer (one single criterion)                                                                                       Confirmed diagnosis of metastatic cancer who present low response or contraindication of specific treatment, progressive outbreak during treatment or metastatic affectation of vital organsSignificant functional deterioration (palliative performance status \<50%)Persistent, troublesome symptoms, despite optimal treatment of underlying condition(s)
  Chronic pulmonary disease (two or more criteria)                                                                    Breathlessness at rest or on minimal exertion between exacerbationsDifficult physical or psychological symptoms despite optimal tolerated therapyFEV1 \<30% or criteria of restricted severe deficit: FVC \<40%/DLCO \<40%Accomplishment of oxygen therapy at home criteriaRecurrent hospital admissions (\>3 admissions in 12 months due to exacerbations)
  Chronic heart disease (two or more criteria)                                                                        Heart failure NYHA stage III or IV, severe valve disease or inoperable coronary artery diseaseShortness of breath at rest or minimal exertionDifficult physical or psychological symptoms despite optimal tolerated therapyEjection fraction severely affected (\<30%) or severe pulmonary hypertension (\>60 mm Hg)Renal failure (GFR \<30 L/min)Repeated hospital admissions with symptoms of heart failure/ischaemic heart disease (\>3 last year)
  Serious chronic liver disease (one single criterion)                                                                Advanced cirrhosis: stage Child C, MELD-Na Score \>30 or with one or more of the following medical complications: diuretic-resistant ascites, hepatorenal syndrome or upper gastrointestinal bleeding due to portal hypertension with failed response to treatmentHepatocellular carcinoma: present, in stage C or D (BCLC)
  Serious chronic renal disease (one single criterion)                                                                Serious renal failures (GFR \<15) in patients to whom substitutive treatment or transplant is contraindicated
  Chronic neurological diseases (1): CVA (one single criterion)                                                       During acute and subacute phases (\<3 months poststroke): persistent vegetative or minimal conscious state \>3 daysDuring the chronic phase (\>3 months poststroke): repeated medical complications (aspiration pneumonia, pyelonephritis, recurrent febrile episodes, pressure ulcers stages 3--4 or dementia with severe criteria poststroke)
  Chronic neurological diseases (2): motor neuron diseases, multiple sclerosis and Parkinson (two or more criteria)   Progressive deterioration in physical and/or cognitive function despite optimal therapyComplex and difficult symptomsSpeech problems with increasing difficulty communicatingProgressive dysphagiaRecurrent aspiration pneumonia, breathless or respiratory failure
  Dementia (two or more of the following criteria)                                                                    Severity criteria: GDS/FAST 6c or more.Progression criteria: loss of two or more ADLs in the last 6 months, despite adequate therapeutic intervention or difficulty swallowing, or denial to eat, in patients who will not receive enteral or parenteral nutritionUse of resources criteria: multiple admissions (\>3 in 12 months, due to concurrent processes---aspiration pneumonia, pyelonephritis, sepsis, etc---that cause functional and/or cognitive decline)
  ------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADL, activities of daily living; BCLC, Barcelona clinic liver cancer; CVA, cerebrovascular accident; DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GFR, glomerular filtration rate; NYHA, New York Heart Association.

Variables and sources of information {#s2c}
------------------------------------

In the selected cohort, we evaluated the indicators included in the NECPAL CCOMS-ICO tool, which were retrieved, if available, from patient\'s clinical records by the investigator team or by clinical judgement after interviewing healthcare professionals (including clinical variables and need, demand and choice requests). In order to reduce systematic error, all definitions, procedures---including data collection---and measures were standardised and followed according to the study operations manual.

Indicators were arranged by domain (functional, nutritional and cognitive status, emotional problems, geriatric syndromes, social vulnerability and others) and according to their static (severity) and dynamic (progression) characteristics, for patients in each of the three end-of-life trajectories associated with advanced chronic illnesses.

### Indicators and diseases {#s2c1}

We evaluated the distribution of the indicators by classifying persons according to the presence of severity and/or progression criteria of the main disease (cancer, chronic pulmonary disease, chronic heart disease, serious chronic liver disease, serious chronic renal disease, chronic neurological diseases and dementia). We refer to the group of patients identified as being NECPAL (+) without severity and/or disease progression criteria as 'advanced frailty patients without advanced disease criteria'.

### Indicators and end-of-life trajectories {#s2c2}

We organised the illnesses according to the described end-of-life trajectories: cancer, organ failure (including lung, heart, hepatic and renal disease) and dementia. As for neurologic diseases, we put together primary neurodegenerative/Alzheimer and neurodegenerative diseases such as Parkinson and amyotrophic lateral sclerosis for easier analysis purposes, given that their clinical evolution tends to be similar to dementia.

Statistical methods {#s2d}
-------------------

Characteristics by domain were reported as averages with SDs for continuous variables (Barthel, Charlson, unplanned admissions and age) or percentages for the categorical variables. All indicators were calculated for the entire sample and for each four categories of patients: cancer, organ failure, dementia/chronic neurological diseases and advanced frailty. We compared the proportions among the four groups using χ^2^ test for categorical variables. Differences for non-categorical variables were assessed using ANOVA tests.

Analyses were performed with the Statistical Package for Social Sciences (SPSS), V.21.0. A two-sided p value \<0.05 was considered to indicate statistical significance.

Results {#s3}
=======

Participants {#s3a}
------------

A total number of 782 NECPAL positive (+) patients (38.5% men; 61.5% women; mean age: 80.89) were recruited from different levels of the health system: 523 (66.9%) residents in the community, 154 (19.7%) in nursing homes, 55 (7%) at the intermediate care centre and 50 (6.4%) at the acute care hospital; this distribution of patients among the diverse settings is representative of the population prevalence of these patients.[@R51] All participants were allocated to one trajectory presented severity and progression criteria for two concomitant organs. The online [supplementary appendix](#SM1){ref-type="supplementary-material"} shows the results for each individual disease.
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Main results {#s3b}
------------

Functional progression (31.5% loss ≥2 activities of daily living (ADLs), 44.3% clinical perception) and nutritional criteria (particularly clinical perception, 30.7%) were the indicators most constantly associated with end-of-life identification in all patients ([table 3](#BMJOPEN2016012340TB3){ref-type="table"}). For the patients with cancer, organ failure and advanced frailty, we could not determine if there were cognitive progression criteria (na), since this feature was only evaluated as a criterion for advanced dementia. Emotional distress (21.9%) and some geriatric syndromes (11.2% falls and 15.7% delirium) were also present, but less frequently and without statistically significant differences among the four groups. Generally, families perceived more palliative needs than the patients and professionals.

###### 

Distribution of indicators per end-of-life trajectory

                                                                   End of life trajectory                                                                                                             
  -------------------------------------------- ------------------- ------------------------ ------------------ ------------------ ------------------ ------------- ----- ----------- ----- ---------- -------------
  Functional                                                                                                                                                                                          
   **S** (Barthel \<25)                        147                 **22.2**                 3                  **4.5**            6                  **5.3**       101   **49.7**    37    **10.6**   **\<0.005**
   **P** (loss ≥2ADL\'s)                       243                 **31.5**                 33                 **43.4**           38                 **30.6**      63    **31.03**   109   **29.4**   0.121
   **P** (clinical perception)                 343                 **44.3**                 45                 **59.2**           54                 **42.9**      84    **41.4**    160   **43**     0.050
  Nutritional                                                                                                                                                                                         
   **S** (albumin \<2.5)                       24                  **5.8**                  5                  **8.1**            6                  **6.4**       1     **0.4**     13    **5.9**    0.560
   **P** (Weight loss \>10%)                   42                  **12.2**                 7                  **23.3**           6                  **11.5**      14    **6.8**     15    **9.7**    0.211
   **P** (clinical perception)                 237                 ** 30.7**                48                 **63.2**           29                 **23**        63    **31.3**    97    **26.3**   **\<0.005**
  Cognitive                                                                                                                                                                                           
   **S** (GDS ≥6c)                             169                 **21.9**                 0                  **0**              0                  **0**         169   **83.2**    0     **0**      **\<0.005**
   **P** (loss ≥2ADL\'s)                       68                  **8.7**                  na                 ** na**            na                 **na**        68    **33.5**    na    **na**     **\<0.005**
  Emotional                                                                                                                                                                                           
   Distress                                    165                 **21.9**                 20                 **24.7**           28                 **22.6**      33    **16.2**    84    **23.8**   0.134
  Geriatric syndromes                                                                                                                                                                                 
   Pressure ulcers                             34                  **4.4**                  3                  **4**              1                  **0.8**       19    **9.3**     11    **3**      **\<0.005**
   Dysphagia                                   81                  **10.4**                 8                  **10.8**           4                  **3.2**       48    **23.6**    21    **5.6**    **\<0.005**
   Falls \>2                                   86                  **11.2**                 7                  **9.5**            9                  **7.3**       26    **12.8**    44    **12**     0.401
   Delirium                                    122                 **15.7**                 10                 **13.2**           17                 **13.5**      38    **18.7**    57    **15.3**   0.518
   Rec. infections                             41                  **5.3**                  3                  **4**              14                 **11.2**      8     **3.9**     16    **4.3**    **0.015**
  Others                                                                                                                                                                                              
   Comorbidity (Charlson average)              **3.23** (±2.9)     **5.34** (±2.6)          **3.38** (±2.1)    **2.28 (**±1.7)    **3.07** (±2.2)    **\<0.005**                                      
   Use of resources                                                                                                                                                                                   
    Unplanned admissions (average, per year)   **0.55** (±1.0)     **0.64** (±0.9)          **1.0** (±1.3)     **0.22** (±0.5)    **0.5** (±1.15)    **\<0.005**                                      
    Complex care                               145                 **19.2**                 26                 **35.1**           27                 **22.1**      28    **13.8**    64    **17.9**   **\<0.005**
   Palliative care approach                                                                                                                                                                           
    Choice/demand patient                      44                  **5.6**                  13                 **17.1**           7                  **5.6**       3     **1.4**     21    **5.6**    **\<0.005**
    Choice/demand family                       209                 **26.7**                 30                 **39.5**           30                 **23.8**      69    **34.0**    80    **21.5**   **\<0.005**
    Need (healthcare professionals)            121                 **15.5**                 36                 **47.4**           21                 **16.9**      27    **13.3**    37    **10**     **\<0.005**
   Age (mean)                                  **80.89** (±11.9)   **79.9** (±24.0)         **77.7** (±13.4)   **82.99** (±9.7)   **82.6** (±11.3)   **\<0.005**                                      
   Sex                                                                                                                                                                                                
    Male                                       301                 **38.5**                 44                 **57.9**           66                 **52.4**      50    **24.6**    141   **37.4**   **\<0.005**
    Women                                      481                 **61.5**                 32                 **42.1**           60                 **47.6**      153   **75.4**    236   **62.6**   

%, Percentage of patients with the presence of the analysed variable with respect to the total of patients (once missing data excluded).

p Values: obtained from comparative analysis among the four groups described: cancer, organ failure, dementia/chronic neurological diseases in advanced frailty.

ADL, activities of daily living; n, number of valid patients for evaluation of variable; na, not applicable; P, progression criteria; S, severity criteria.

The functional severity criteria, cognitive severity criteria, some geriatric syndromes such as decubitus ulcers, dysphagia and repetition infections, comorbidity, use of resources, election criteria, demand and need of PC and age and gender showed statistically significant differences in the classification per trajectories performed. Patients with advanced cancer rarely presented with functional severity criteria (4.5%). For these patients, the presence of nutritional progression criteria was more common than in the other groups (clinical perception: 63.2%). There was a high need of complex care (35.1%), as well as demand and need of PC from the patients (17.1%), relatives (39.5%) and professionals (47.4%).Patients with advanced organ disease---all had main disease severity and progression criteria---presented less parameters of general severity and progression than the rest of trajectories and a lower percentage of geriatric syndromes. In contrast, they presented a larger percentage of systemic infections (11.2%) and more unplanned admissions than the other groups.Patients with advanced dementia and those with chronic neurological diseases presented severity criteria, functional (49.7%) and cognitive (83.2%), and geriatric syndromes: ulcers (9.3%), persistent dysphagia (23.6%), repetitive falls (12.8%) and delirium (18.7%). These patients presented less need of resources than the other groups, and there was a low perception of palliative needs among the professionals (13.3%) compared to relatives (34%).48.2% of the whole NECPAL(+) patients did not present severity and progression criteria for any chronic disease. In comparison with the other trajectories, no indicator in this group ('advanced frailty patients with no advanced disease criteria') was especially prevalent or relatively infrequent: for instance, these patients present more functional severity criteria (10.6%) than patients with cancer (4.5%) and patients with organ failure (5.3%), but lower than patients with dementia (49.7%); they present less nutritional progression criteria (9.7%) than patients with cancer (23.3%) and patients with organ failure (11.5%), but more than patients with dementia (6.8%) or they have more comorbidities (Charlson: 3.07) than patients with dementia (2.28), but less than patients with cancer (5.34) and patients with organ failure (3.38). Globally, professionals had low perceptions that these patients had palliative needs.

Discussion {#s4}
==========

Key results {#s4a}
-----------

Dynamic indicators are more discriminating than static ones to identify PACC.[@R19] Functional and nutritional progression criteria (also cognitive progression could be included if there is delirium)[@R57] are also important, mainly regarding functional loss.[@R58] [@R59] This fact is supported by the literature, given the evidence that changing variables have been shown to have better prognostic ability than those variables that remain stable.[@R19] [@R58] [@R59] Also emotional distress and some geriatric syndromes, though less significantly, have been shown to be useful indicators for early identification.

Beyond the described parameters, we consider that there are no unique and specific indicators to reliably identify PACC, since only a low percentage of patients present most of them. This fact has two implications: (1) early identification of PACC requires a multidimensional evaluation including a wide range of indicators and (2) the different characteristics of these indicators in the diverse groups (cancer, organ disease and dementia/advanced neurologic disease) support the conceptual model of end-of-life trajectories. This model seems to be consistent beyond the described functional dimension: in many of the other dimensions (nutritional, cognitive, geriatric syndromes and use of resources), the behaviour is also different among the groups.

Regarding the differences of the variables in the three end-of-life trajectories, the low prevalence of patients with advanced cancer and functional severity criteria is remarkable; this could be due to a faster decline of these patients in the second transition---if we assume that most patients of this cohort were stable,[@R60] although it could also be due to a selection bias on the part of recruitment process. The impact of undernourishment as an important marker of end of life in patients with cancer is also consistent with the literature.[@R63] For patients with advanced organ diseases, there are more unplanned admissions, probably because of episodes of acute failure or infections, in keeping with the trajectory classically described cohort.[@R44] [@R52] [@R67] As for patients with dementia or with other neurological diseases the criteria of disease severity (frequently based on the functional repercussions of the severity) determine the identification of the end-of-life situation.[@R75] [@R76] This fact, together with the presence of multiple geriatric syndromes, can help professionals in this process of identification.[@R77] The slow and progressive process of decline determines less use of resources and, probably, less perception of PC needs from the professionals, in contrast to the relatives\' view. This analysis endorses the conceptual approach of typical trajectories of decline in advanced chronic illnesses.

However, with mutimorbidity the norm at the end of life, patients may embrace one or more trajectories.[@R78] [@R79] This resulted in an extremely heterogeneous behaviour of the variables over time among different patients.

It was remarkable that in a particularly disease-centred clinical context, practically half of the cohort did not meet advanced disease criteria ('advanced frailty patients with no advanced disease criteria'), but were identified as persons with advanced chronic conditions and PC needs at the same time (NECPAL+); it is estimated that 40% of deaths occur in frail older people who have no main overriding diagnosis.[@R80] This is relevant because it suggests that for early identification for PC it is essential to look beyond disease-centred variables and that multiple general indicators in different domains need to be considered.[@R81] Given that frailty is the most prevalent condition as people approach death,[@R82] a rational clinical approach to these patients would be to consider frailty not as an independent entity defining only one of the end-of-life trajectories, but as a quantitative measurement system to determine the reserve level of the patient. Such reserve would act as the basis for a 'situational diagnosis'. Analysis shows that most variables are present in the end-of-life trajectories, although they behave differently. It may be that with frail patients, the other non-physical trajectories of need may be important to monitor clinically, as they may show more dynamic needs for care.[@R83] More research will be needed to substantiate this claim.

Finally, patients with cancer and patients without cancer present physical decline and significant psychosocial difficulties, and all these patients could benefit from a PC approach. However, healthcare professionals currently identify less patients for a palliative approach for the non-cancer group.[@R84] This might be because the end-of-life trajectory is less predictable for these patients, but this should not stop identifying these patients according to these indicators, rather than professionals having a prognostic paralysis.[@R85]

Strengths and limitations {#s4b}
-------------------------

The study was carried out with 100% of participation from healthcare professionals and settings invited. A standardised case identification methodology was followed in all settings, and a high level of commitment from all participants was gained.

The study has limitations. Since this study was based on health professionals\' assessment and routine data, patients\' perspectives were not included. Availability of quantitative data in clinical charts may have affected description of patients\' characteristics. The study results may have also been affected by the ageing population and strong influence of geriatric care in the area, as well as by the length of the study window. Additionally, a problem of over identification with the tool cannot be dismissed, due to the high number of 'advanced frailty patients with no advanced disease criteria'. We are currently monitoring the mortality of this cohort to confirm or reject this hypothesis.

There was a significant number of missing nutritional indicators requiring an objective measure (47.2% due to albumin or 56% due to weight loss)¾see online [supplementary appendix](#SM1){ref-type="supplementary-material"}. This fact emphasises some discordance between the importance of measuring the nutritional state according to scientific evidence[@R20] and the real clinical practice; we wonder whether using other parameters in the evaluation of undernourishment such as body mass index or mini nutritional assessment[@R86] results would be indicated. Some of the indicators described in the background section, such as social vulnerability or symptoms, were not included in the NECPAL CCOMS-ICO tool. Thus, these could not be assessed in the study; similarly, the progression criteria for dementia could only be assessed for patients with severity criteria of dementia.

The proposal of grouping neurologic diseases including neurodegenerative diseases such as Parkinson and amyotrophic lateral sclerosis with the group of primary neurodegenerative/Alzheimer is arguable; however, it might have not effected final results, given the low number of patients (n=31, 4% of the total cohort).

Generalisability and future trends {#s4c}
----------------------------------

More studies are needed to corroborate these data. However, the results described are a useful basis for future research on the early identification of PACC for integrated PC. Suggested topics to be developed include The cohort corresponds to persons identified a priori as PACC and likely to die in the foreseeable future. It will be necessary, however, to analyse the behaviour of these variables in relation to mortality. We are currently monitoring the cohort at 24 months.Given the large prevalence of advanced frailty patients, new frameworks[@R8] and tools[@R87] based on knowledge on geriatrics, primary care and PC are indicated. In fact, these three areas already share methods regarding care process:[@R88] team work, multidimensional assessment, patient-centred care, psychosocial and caregivers support. More shared research between these specialties and public health will best take this agenda forward together.The conceptual link between the need of multidimensional evaluation of PACC and the high prevalence of advanced frailty patients with no advanced disease criteria can be found in the evaluation of the level of reserve of these patients. Frailty indices,[@R89] already proved to have a strong association with mortality, may become the gold standard for situational diagnosis, since they allow to quantify people\'s health reserves from a universal and objective point of view.

Conclusions {#s5}
===========

Learning from the behaviour of end-of-life indicators helps clinicians deal with the clinical complexity and innate prognostic uncertainties of this group of patients.

There are indicators of PC needs common to all types of trajectories, and others associated with specific trajectories: dynamic variables most consistently identify PACC and PC needs, regardless of the patient\'s end-of-life trajectory. Additionally, the analysis of the other indicators allows us to develop useful knowledge relating to how people die in different ways. To explore in detail the characteristics of the indicators in these patients will help to provide them with patient-centred care.

Almost half of the cohort, although identified as PACC, did not have severe or progression advanced disease. This fact is particularly relevant and highlights the need for more research, probably by using new measuring systems for frailty, and the need of alternative conceptual models, probably by defining new end-of-life trajectories, in order to provide better end-of-life care to this great number of people.
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